PMRS Continues Campaign Against Other Abuse Deterrent Opioid Products

Latest citizen petition seeks to halt US FDA approval of Mallinckrodt's immediate release oxycodone abuse deterrent formulation; user fee action date is Nov. 16.

Opioid Oxycodone crushed

Defeated in its effort to win US FDA approval of its immediate-release oxycodone product, Pharmaceutical Manufacturing Research Services Inc. is now trying to block other opioids with abuse deterrent labeling from clearing the agency.

The company's latest salvo is a citizen petition requesting that FDA not approve Mallinckrodt PLC's abuse deterrent oxycodone...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Product Reviews

More from Pink Sheet